Euphorbia pulcherrima: Subsidiary company's innovative drug APH03621 tablet receives acceptance of clinical trial registration application.

Announcement of Amaryllis: The drug clinical trial application for the innovative drug APH03621 developed independently by Amaryllis Pharmaceuticals Co., Ltd. has been accepted by the National Medical Products Administration, and has received the "Acceptance Notice". APH03621 is a novel, orally administered, non-peptide small molecule gonadotropin-releasing hormone receptor antagonist developed by the company, intended for the treatment of endometriosis. Currently, there are no approved orally administered small molecule GnRH receptor antagonists on the market in China.